Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: A subgroup analysis of a phase 2 randomized controlled study of dialysis patients

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Hutchison, Alastair J ^a,b   Gill, Maggie ^c   Copley, J Brian ^d   Poole, Lynne ^c   Wilson, Rosamund J ^e  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Shire Pharmaceuticals   (United Kingdom)

^d SHIRE   (United States)

^e Granary House   (United Kingdom)

Author keywords

Chronic kidney disease; Lanthanum carbonate; Nutrition; Peritoneal dialysis; Phosphate control

Indexed keywords

LANTHANUM CARBONATE; PHOSPHATE; PLACEBO; VANCOMYCIN;

ABDOMINAL DISTRESS; ADULT; ANAPHYLACTIC SHOCK; ARTICLE; BLOATING; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; FEMALE; FLATULENCE; FOLLOW UP; HOSPITAL DEPARTMENT; HUMAN; HYPERPHOSPHATEMIA; INDIGESTION; INFECTION; LOOSE FECES; MALE; MENORRHAGIA; MOUTH ULCER; MULTICENTER STUDY; NAUSEA; NUTRITIONAL PARAMETERS; PERITONITIS; PHASE 2 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RETROSTERNAL PAIN; SEX RATIO; SHOULDER PAIN; TOOTH DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM; VOMITING;

DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERPHOSPHATEMIA; LANTHANUM; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PLACEBO EFFECT; TREATMENT OUTCOME;

EID: 84873938844     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-40     Document Type: Article

References (25)

1. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Block GA, Hulbert-Shearon TE, Levin NW, Port FK, Am J Kidney Dis 1998 31 607 617 10.1053/ajkd.1998.v31.pm9531176 9531176
2. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Block GA, Port FK, Am J Kidney Dis 2000 35 1226 1237 10.1016/S0272-6386(00)70064-3 10845841 (Pubitemid 30354431)
3. Serum phosphate levels and mortality risk among people with chronic kidney disease. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL, J Am Soc Nephrol 2005 16 520 528 10.1681/ASN.2004070602 15615819 (Pubitemid 41725150)
4. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM, J Am Soc Nephrol 2004 15 2208 2218 10.1097/01.ASN.0000133041.27682.A2 15284307 (Pubitemid 39031360)
5. National kidney foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Eknoyan G, Levin A, Levin N, Am J Kidney Dis 2003 42 Suppl 3 1 S201 14520607
6. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Shinaberger CS, Greenland S, Kopple JD, Van Wyck D, Mehrotra R, Kovesdy CP, Kalantar-Zadeh K, Am J Clin Nutr 2008 88 1511 1518 10.3945/ajcn.2008.26665 19064510
7. Home dialysis in the new USA bundled payment plan: implications and impact. Golper TA, Guest S, Glickman JD, Turk J, Pulliam JP, Perit Dial Int 2011 31 12 16 10.3747/pdi.2010.00143 21282384
8. Confounding effect of comorbidities and malnutrition on survival of peritoneal dialysis patients. Prasad N, Gupta A, Sinha A, Sharma RK, Saxena A, Kaul A, Bhaduria D, Gupta A, J Ren Nutr 2010 20 384 391 10.1053/j.jrn.2010.01. 001 20226687
9. Protein and energy intake, nitrogen balance and nitrogen losses in patients treated with continuous ambulatory peritoneal dialysis. Bergström J, Fürst P, Alvestrand A, Lindholm B, Kidney Int 1993 44 1048 1057 10.1038/ki.1993.347 8264134 (Pubitemid 23316473)
10. Regression equation predicts dietary phosphorus intake from estimate of dietary protein intake. Boaz M, Smetana S, J Am Diet Assoc 1996 96 1268 1270 10.1016/S0002-8223(96)00331-8 8948388 (Pubitemid 27381750)
11. Metabolic consequences of peritoneal dialysis treatment. Gallieni M, Musetti C, Granata A, Olivi L, Bertoli S, Panminerva Med 2009 51 175 185 19859052
12. Influence of dialysate on gastric emptying time in peritoneal dialysis patients. Van Vlem BA, Schoonjans RS, Struijk DG, Verbanck JJ, Vanholder RC, Van Biesen WV, Lefebvre RA, De Vos MP, Lameire NH, Perit Dial Int 2002 22 32 38 11929141 (Pubitemid 34326577)
13. Dyslipidemia in peritoneal dialysis-relation to dialytic variables. Johansson AC, Samuelsson O, Attman PO, Haraldsson B, Moberly J, Knight-Gibson C, Alaupovic P, Perit Dial Int 2000 20 306 314 10898048 (Pubitemid 30497169)
14. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Lindholm B, Norbeck HE, Acta Med Scand 1986 220 143 151 3776689 (Pubitemid 16005529)
15. Daily protein intake and survival in patients on peritoneal dialysis. Dong J, Li Y, Xu Y, Xu R, Nephrol Dial Transplant 2011 26 3715 3721 10.1093/ndt/gfr142 21430179
16. Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study. Martin P, Wang P, Robinson A, Poole L, Dragone J, Smyth M, Pratt R, Am J Kidney Dis 2011 57 700 706 10.1053/j.ajkd.2010.11.028 21354682
17. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Hutchison AJ, Barnett ME, Krause R, Kwan JTC, Siami GA, SPD405-309 lanthanum study group, Nephron Clin Pract 2008 110 15 c23 10.1159/000149239 18667837
18. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Al-Baaj F, Speake M, Hutchison AJ, Nephrol Dial Transplant 2005 20 775 782 10.1093/ndt/gfh693 15703206 (Pubitemid 40520656)
19. Serum albumin as a predictor of mortality in peritoneal dialysis: comparisons with haemodialysis. Mehrotra R, Duong U, Jiwakanon S, Kovesdy CP, Moran J, Kopple JD, Kalantar-Zadeh K, Am J Kidney Dis 2011 58 418 428 10.1053/j.ajkd.2011.03.018 21601335
20. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study. Lee YK, Choi HY, Shin SK, Lee HY, Clin Nephrol 2012 Dec 4 [Epub ahead of print]
21. Lanthanum carbonate treatment of patients with hyperphosphatemia undergoing CAPD. Kawanishi H, Ishida M, Ishizaki M, Takuma Y, Tamura H, Kobayashi S, Tamura T, Ohashi H, Hiramatsu M, Minakuchi J, Hirakata H, Shigematsu T, Perit Dial Int 2008 28 673 675 18981401
22. Lanthanum carbonate for hyperphosphatemia in patients on peritoneal dialysis. Ohno M, Ohashi H, Oda H, Yokoyama H, Okada M, Nagaya M, Izumi K, Ito H, Katoh S, Perit Dial Int 2012 [Epub ahead of print]
23. Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialysis patients. Yamada S, Yoshida H, Taniguchi M, Tanaka S, Eriguchi M, Nakano T, Tsuruya K, Kitazono T, Intern Med 2012 51 2097 2104 10.2169/internalmedicine.51.6814 22892485
24. Clinical practice guidelines for nutrition in chronic renal failure K/DOQI, National kidney foundation. Eknoyan G, Levin N, Am J Kidney Dis 2000 35 1 S140 10895784
25. Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study. Vemuri N, Michelis MF, Matalon A, BMC Nephrol 2011 12 49 10.1186/1471-2369-12-49 21962172